{"id":478213,"date":"2024-01-05T21:40:42","date_gmt":"2024-01-06T02:40:42","guid":{"rendered":"https:\/\/platohealth.ai\/management-moves-abound-on-eve-of-jpm-including-new-chairs-for-sobi-corteria\/"},"modified":"2024-01-06T15:25:23","modified_gmt":"2024-01-06T20:25:23","slug":"management-moves-abound-on-eve-of-jpm-including-new-chairs-for-sobi-corteria","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/management-moves-abound-on-eve-of-jpm-including-new-chairs-for-sobi-corteria\/","title":{"rendered":"Management moves abound on eve of JPM, including new chairs for Sobi,\u00a0Corteria","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Management Tracks<\/p>\n

\n
\n
\n

Plus: Zaderej to retire as AxoGen CEO and updates from AxoGen, Delfi, Illumina, Evozyne, Kiyatec, Sosei, Twist, Novocure, Be Bio, Novo Holdings<\/a>, Bioluminescence and more<\/h2>\n

\n By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n

January 6, 2024 2:40 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Bo Jesper Hansen resigned as chairman <\/span>of  Swedish Orphan Biovitrum AB<\/a><\/b> (SSE:SOBI) for health reasons. Hansen is succeeded by Annette Clan<\/span>cy, a 30-year veteran of GSK plc (LSE:GSK; NYSE:GSK) and Sobi board member since 2014.<\/p>\n

Corteria Pharmaceuticals S.A.S.<\/a><\/b>, named <\/span>Mark Pruzanski as chairman, succeeding Thierry Laugel, a managing partner at Kurma Partners, who will remain on the board. Pruzan<\/span>ski founded and was CEO of Intercept Pharmaceuticals Inc., then chairman and CEO of Versanis Bio Inc. until its acquisition<\/a> by Eli Lilly and Co. (NYSE:LLY). Corteria is advancing<\/a> a preclinical pipeline of heart failure therapies to treat different patient subsets. …<\/p>\n